



Thank you for your interest in AiViva and taking the time to request our Investor Brief. We're excited you are interested in learning more about our investment opportunity!

Our mission is to address critically unmet medical needs, transforming treatment paradigms through focal therapies and novel medical applications in ophthalmology, dermatology, and oncology.

It takes a community to disrupt an industry

AiViva has opened its investor community on StartEngine to those who want to join our mission!

We think there's a huge opportunity to partner with the community of people who share our vision of revolutionizing the biotech and pharma industries.

Check out our campaign video below.

We've designed a number of perks for our investors who want to jump aboard and invest.

Together we can take an entire industry by storm

Visit our fund raise page at <https://www.startengine.com/aiviva> to learn more about AiViva and how you can join our investment opportunity.

Warmly,

Team AiViva



Investment Presentation

Corporate Overview


June 2022



AiViva At a Glance

Overview:

- Founded: 2015
- HQ: Newport Beach, CA
- A clinical stage biopharma company, created to address high unmet needs in
 - Ophthalmology
 - Oncology
 - Urology
 - Dermatology
- Using our proprietary JEL™ technology and other drug delivery methods.
- Novel drug delivery for enhanced safety, efficacy, and reduced treatment burden
 - Targeted local efficacy
 - Prolonged treatment effect
 - Minimal systemic exposure/side effects
- Strong Patent Position
 - 63+ Worldwide patent applications, expected expiry date 2038 – 2042+



Portfolio Provides Broad Therapeutic Potential

Ophthalmology

nAMD • DME • RVO
Uveitis • Pterygium • Eye
Surgery Fibrosis

Dosing frequency:
6 Month • 12 Month

\$10Bn*

Dermatology

Scarring • NMSC
Rosacea • Keloids

Dosing frequency:
1 Month • 3 Month

\$12.3Bn**

Oncology/Urology

Thyroid Tumor •
Pancreatic Tumor •
Hepatocellular Carcinoma
• Renal Cell Carcinoma •
Prostate Cancer • BPH

Dosing frequency:
6 Month • 12 Month

\$7.3Bn*** / 10Bn****

Global Market Size

High value markets that are growing and in need of new treatments

* <https://www.psmarketresearch.com/market-analysis/wet-age-related-macular-degeneration-market>

** <https://www.grandviewresearch.com/industry-analysis/scar-treatment-market>

*** <https://www.alliedmarketresearch.com/prostate-cancer-medicine-market>

**** <https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-treatment-bph-market>

Proprietary JEL™ Delivery Platform Offers Optimal Focal Delivery

JEL™ Technology allows for customizable drug-release profiles, optimizing drug durability and development of novel, indication-specific formulations in multiple therapeutic areas



Bio-dissolvable

Forms drug depot at the site of the disease


Sterilizable

Turns to gel at body temperature in a minute

Liquid that can be administered via a needle or cannula

Stable at storage

Strong IP



Development Timeline of Portfolio

PROGRAM	PRECLINICAL	PHASE 1 / 2	MILESTONE
DERMATOLOGY			
AIV001-W01 Surgical Scar Prevention			Positive Human Proof of Concept
AIV001-W02 Keloidectomy Scar Management			Topline 2023
OPHTHALMOLOGY			
AIV007-E01 wet AMD			Positive Human Proof of Concept
AIV007-E02 wet AMD			Trial initiate 2023
ONCOLOGY			
AIV001-C01 Non-Melanoma Skin Cancer			Topline 2023
EARLY STAGE PROGRAMS			
Oncology, Solid Tumors			Preclinical POC studies completed, select lead indication to advance
Urology, Prostate Disorders			IND-enabling Phase

Comprehensive Intellectual Asset Portfolio

63+ Worldwide patent applications (granted and pending), including 4 issued orange bookable patent families, expected expiry date 2038 – 2042+

METHOD OF USE PATENTS					DELIVERY PATENTS	
Method for using TKI to treat skin-related disorder	Method for using TKI to treat eye-related disorder	Method for using TKI to treat BPH-related disorder	Method for using TKI to treat rosacea-related disorder (1 st & 2 nd)	Method for using TKI to treat uterine fibroids related disorder	Aqueous suspension comprising at least one multi-target inhibitor	JEL™ reverse-thermal-gelation material
Granted Application US, KR, CN, AUS	Granted Application AUS, JP, KR, US	Granted Application AUS, US, CA	Granted Application AUS, TW, JP, CA, KR	Granted Application AUS, CA, US	Pending Application US, CA, EP, AUS, CN, JP, KR, TW	Pending Application US, CA, EP, AUS, CN, JP, KR, TW
Pending Application US, CA, EP, JP	Pending Application US, CA, EP, CN	Pending Application EP, CN, JP, KR	Pending Application US, EP, CN	Pending Application US, EP, CN, JP, KR		

Accomplished Management Team and Board

Management Team



Diane Tang-Liu, Ph.D.,
FAAPS, FCP
President & CEO



Darlene Deecher, Ph.D.
VP Clinical Development



Shane D. Cerrato
VP Business Development



Board of Directors



Jinn Wu, Ph.D.
Board Chairman



Larry Hsu, Ph.D.
Board Member



Johnson Lau,
MBBS, MD, FRCP
Board Member



Diane Tang-Liu,
Ph.D., FAAPS, FCP
Board Member



Value Proposition

- ✓ **Novel technologies** to reduce treatment burden and improve benefit-risk profiles
- ✓ **Risk-mitigated development strategy** by use of validated therapeutics
- ✓ **Diverse pipeline** with multiple high-value indications
- ✓ **Strong IP position** for new uses, products, and technologies
- ✓ **Experienced team** with proven track record and stellar execution



Website: www.aiviva.com
E-mail Address: office@aiviva.com

